Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tamsulosin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Tamsulosin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-001211-37 Sponsor Protocol Number: 905-CL-055 Start Date*: 2009-07-16
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double-blind, parallel group, placebo controlled, multi-center study of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg and ...
    Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) FR (Completed) SK (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Completed) HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001380-23 Sponsor Protocol Number: TASTE-001 Start Date*: 2020-02-21
    Sponsor Name:Franciscus Gasthuis en Vlietland
    Full Title: The effect of tamsulosin on the spontaneous passage of bile stones
    Medical condition: Choledocholithiasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001212-20 Sponsor Protocol Number: 905-CL-057 Start Date*: 2009-07-16
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male ...
    Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) DE (Completed) FR (Completed) HU (Completed) SK (Completed) BE (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002072-18 Sponsor Protocol Number: 905-CL-052 Start Date*: 2006-12-13
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared wi...
    Medical condition: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) CZ (Completed) DE (Completed) PT (Completed) SK (Completed) FI (Completed) HU (Completed) GB (Completed) BE (Completed) DK (Completed) FR (Completed) AT (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019469-26 Sponsor Protocol Number: pRGF/016/09 Start Date*: 2010-07-29
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. NHS Grampian
    Full Title: Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: a multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine)and an alpha b...
    Medical condition: Use of drug therapy in the management of symptomatic ureteric stones in hospitalised adults: multicentre placebo controlled randomised trial of a calcium channel blocker(nifedipine) and an alpha bl...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003064-36 Sponsor Protocol Number: DEF_Version_1.2 Start Date*: 2015-11-10
    Sponsor Name:Vienna Institute for Research in Ocular Surgery
    Full Title: Impact of selective alpha 1A receptor antagonists on the pupil size after instillation of tropicamide 0.5% and phenylephrine 10%
    Medical condition: Impact of selective alpha 1A receptor antagonists on the pupil size after instillation of tropicamide 0.5% and phenylephrine 10%
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003061-28 Sponsor Protocol Number: PDS_Version_1.2 Start Date*: 2015-09-08
    Sponsor Name:Vienna Institute for Research in Ocular Surgery
    Full Title: Effect of selective alpha 1A receptor antagonists on the iris dilator muscle
    Medical condition: Effect of selective alpha 1A receptor antagonists on the iris dilator muscle
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001627-11 Sponsor Protocol Number: 617-EC-006 Start Date*: 2005-10-03
    Sponsor Name:Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V., as of August 2005)
    Full Title: A randomized, double-blind, placebo-controlled study to assess the effect of Tamsulosin OCAS 0.4 mg tablets, once daily on nocturia, compared to placebo, in patients with lower urinary tract sympto...
    Medical condition: LUTS (lower urinary tract symptoms) associated with BPH (benign prostatic hyperplasia)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) IE (Completed) GB (Completed) CZ (Completed) DK (Completed) ES (Completed) HU (Completed) FI (Completed) IT (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010739-42 Sponsor Protocol Number: H6D-MC-LVID Start Date*: 2009-10-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) NL (Completed) BE (Completed) AT (Completed) IT (Completed) FR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003620-20 Sponsor Protocol Number: P101005 Start Date*: 2013-06-04
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Tamsulosin to prevent the failures of early bladder catheter removal after acute urinary retention in elderly women hospitalized for an acute medical problem
    Medical condition: urinary disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10001055 Acute retention of urine LLT
    Population Age: Elderly Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004423-11 Sponsor Protocol Number: 527.66 Start Date*: 2007-01-22
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: An uncontrolled, open-label, titration, long-term safety (up to 12 months) and efficacy study of tamsulosin hydrochloride in children with neuropathic bladder, with a randomized pharmacokinetic sub...
    Medical condition: Neurogenic Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029279 Neurogenic bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022111-19 Sponsor Protocol Number: FDC114615 Start Date*: 2010-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003048-52 Sponsor Protocol Number: 527.51 Start Date*: 2007-10-29
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A Phase IIb/III, multi-centre, double-blind, randomised, placebo-controlled, dose ranging study of tamsulosin hydrochloride (low, medium and high dose) as treatment in children with neuropathic bla...
    Medical condition: Neurogenic Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029279 Neurogenic bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001602-24 Sponsor Protocol Number: Th.B-1(2007):BTX(CP/CPPS) Start Date*: Information not available in EudraCT
    Sponsor Name:Department of Urology and Pediatric Urology - Justus-Liebig-University Giessen
    Full Title: Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS)
    Medical condition: chronic prostatitis / chronic pelvic pain syndrom
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021965 Inflammation pelvic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001268-57 Sponsor Protocol Number: 905-CL-058 Start Date*: 2007-09-12
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlo...
    Medical condition: Storage and Voiding Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027561 Micturition disorder LLT
    9.1 10005053 Bladder neck obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005665-11 Sponsor Protocol Number: KMD3213-IT-CL 0215 Start Date*: 2006-03-23
    Sponsor Name:Recordati S.p.A
    Full Title: Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Cont...
    Medical condition: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004446 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-004036-36 Sponsor Protocol Number: 178-MA-1008 Start Date*: 2016-07-18
    Sponsor Name:Astellas Pharma Global development, Inc
    Full Title: A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi- Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While ...
    Medical condition: Over active bladder (OAB) in men with Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10046543 Urinary incontinence PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000946-16 Sponsor Protocol Number: TryptoBPH Start Date*: 2021-12-17
    Sponsor Name:Centro Clínico Académico - Braga, Associação (2CA-Braga)
    Full Title: TryptoBPH - Proof-of-concept study to evaluate the safety and efficacy of tryptophan in patients with BPH
    Medical condition: Benign Prostate Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10065030 BPH LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012986-67 Sponsor Protocol Number: JJalpha-2009 Start Date*: 2009-11-19
    Sponsor Name:CHU DE POITIERS
    Full Title: Evaluation of the efficacy of Tamsulosine (alpha blockers) compared to phloroglucinol in improving JJ ureteral stent tolerance. A randomized controlled trial.
    Medical condition: Confirmed or potential ureteral obstruction with a uretral stenting indication.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10050307 Ureteral stent insertion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022138-10 Sponsor Protocol Number: FI.LU.VA Start Date*: 2010-07-28
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: A SINGLE-CENTRE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF COMBINATION THERAPY WITH VARDENAFIL 10 mg AND TAMSULOSIN 0,4 mg IN THE TREATMENT OF MEN WITH PER...
    Medical condition: men with persistent irritative urinary symptoms
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038359 - Renal and urinary disorders 10005034 Bladder discomfort PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 02:54:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA